Nairametrics
  • Home
  • Exclusives
    • Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Ranking & Reviews
  • Markets
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
  • Industries
    • Company News
    • Consumer Goods
    • Content Partners
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
  • Economy
    • Macro-Economic News
    • Get Data
  • General News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
No Result
View All Result
  • Home
  • Exclusives
    • Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Ranking & Reviews
  • Markets
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
  • Industries
    • Company News
    • Consumer Goods
    • Content Partners
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
  • Economy
    • Macro-Economic News
    • Get Data
  • General News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
No Result
View All Result
Nairametrics
No Result
View All Result
Home General News Coronavirus

Low-cost version of Merck COVID pill to be made for less-developed nations

Chidinma Anyalewechi by Chidinma Anyalewechi
January 20, 2022
in Coronavirus
Australia to buy 300,000 Merck’s Covid-19 capsule as cases hit record high
Share on FacebookShare on TwitterShare on Linkedin

Almost 30 generic drugmakers have struck a deal with a UN-backed agency to make cheaper or low-cost versions of the Covid-19 recently approved pill, Molnupiravir, produced by Merck & Co’s (MRK.N).

The low-cost versions of the pill will be produced for nations who cannot afford the Merck pill, thereby widening access to a drug seen as a weapon in fighting the pandemic.

In December, the antiviral drug received emergency approval in the United States and according to clinical trial results has shown a potential to reduce hospitalizations and deaths of high-risk patients by around 30%.

The agreement has been reached by the U.N.-backed Medicines Patent Pool (MPP) and Merck & Co’s.

This agreement grants the 27 generic drugmakers from India, China and other countries in Africa, Asia and the Middle East, the go-ahead to produce ingredients and the finished drug.

According to the MPP, the details of the deal stipulates that the pill would be distributed to 105 less-developed nations.

It is also worthy of note that the developers of molnupiravir, that is, Merck & Co’s, a U.S. firm Ridgeback Biotherapeutics and Emory University, will not receive royalties for the sale of the low-cost versions produced by generic drugmakers so long as COVID-19 remains classified as a Public Health Emergency of International Concern by the World Health Organization (WHO).

The Executive Director of the MPP, Charles Gore, said, “This is a critical step towards ensuring global access to an urgently needed COVID-19 treatment and we are confident that, as manufacturers are working closely with regulatory authorities, the anticipated treatments will be rapidly available.”

Other pharmaceuticals involved in the production of the low-cost pill are; Bangladesh’s Beximco Pharmaceuticals, India’s Natco Pharma (NATP.NS), South Africa’s Aspen Pharmacare Holdings (APNJ.J) and China’s Fosun Pharma are among generics firms that will produce the finished product.

Related

Tags: Covid-19Merck COVID pillMolnupiravirWHOWorld Health Organization

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Access Bank
Bankers Committee
Flowmono

Bfpeer
Mega Millions
FCMB
Ikeja Electrics
Zenith CEX
Kwakol Markets
First bank





    Business News | Stock Market | Money Market | Cryptos | Financial Literacy | SME |

    Recent News

    • Why cost of economy flight ticket may hit N100,000 soon
    • A16z launches $600 million fund dedicated to gaming and Web3
    • Bored Ape Yacht Club’s floor price drops by 55% in May

    Follow us on social media:

    Recent News

    Bored Ape Yacht Club’s floor price drops by 55% in May

    Bored Ape Yacht Club’s floor price drops by 55% in May

    May 19, 2022
    Naira dollar

    Naira depreciates at I&E window despite significant improvement in FX supply

    May 19, 2022
    • ABOUT US
    • CONTACT US
    • PRODUCTS
    • ANDROID APP
    • iOS APP
    • DISCLAIMER
    • CAREERS
    • PRIVACY POLICY

    © 2022 Nairametrics

    No Result
    View All Result
    • Home
    • Exclusives
      • Analysis
      • Corporate Stories
      • Interviews
      • Investigations
      • Ranking & Reviews
    • Markets
      • Cryptos
      • Commodities
      • Equities
        • Dividends
        • Stock Market
      • Fixed Income
      • Market Views
    • Industries
      • Company News
      • Consumer Goods
      • Content Partners
      • Corporate deals
      • Corporate Press Releases
      • Energy
      • Entertainment
      • Financial Services
      • Hospitality & Travel
      • Manufacturing
    • Economy
      • Macro-Economic News
      • Get Data
    • General News
    • Financial Literacy
      • Career tips
      • Personal Finance
    • Lifestyle
      • Billionaire Watch
      • Profiles
    • Opinions
      • Blurb
      • Op-Eds

    © 2022 Nairametrics

    Social Media Auto Publish Powered By : XYZScripts.com